BRPI0413204A - terapia de combinação para controle glicêmico - Google Patents

terapia de combinação para controle glicêmico

Info

Publication number
BRPI0413204A
BRPI0413204A BRPI0413204-1A BRPI0413204A BRPI0413204A BR PI0413204 A BRPI0413204 A BR PI0413204A BR PI0413204 A BRPI0413204 A BR PI0413204A BR PI0413204 A BRPI0413204 A BR PI0413204A
Authority
BR
Brazil
Prior art keywords
combination therapy
glycemic control
control combination
diabetes mellitus
niddm
Prior art date
Application number
BRPI0413204-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Hans-Ulrich Demuth
Konrad Glund
Mathias Hoffmann
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of BRPI0413204A publication Critical patent/BRPI0413204A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
BRPI0413204-1A 2003-09-02 2004-09-02 terapia de combinação para controle glicêmico BRPI0413204A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49953503P 2003-09-02 2003-09-02
PCT/IB2004/003082 WO2005020983A2 (en) 2003-09-02 2004-09-02 Combination therapy for glycaemic control

Publications (1)

Publication Number Publication Date
BRPI0413204A true BRPI0413204A (pt) 2006-10-03

Family

ID=34272835

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413204-1A BRPI0413204A (pt) 2003-09-02 2004-09-02 terapia de combinação para controle glicêmico

Country Status (14)

Country Link
US (1) US20060287251A1 (enExample)
EP (1) EP1663200A2 (enExample)
JP (1) JP2007504213A (enExample)
KR (1) KR20060119927A (enExample)
CN (1) CN1845731A (enExample)
AU (1) AU2004267955A1 (enExample)
BR (1) BRPI0413204A (enExample)
CA (1) CA2536432A1 (enExample)
EA (1) EA200600356A1 (enExample)
IL (1) IL173844A0 (enExample)
MX (1) MXPA06002127A (enExample)
NO (1) NO20061085L (enExample)
WO (1) WO2005020983A2 (enExample)
ZA (1) ZA200601770B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526291D0 (en) * 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
GB0623892D0 (en) * 2006-11-29 2007-01-10 Medical Res Council Technology Assay
CN102933598A (zh) * 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
CA2851690C (en) * 2011-10-28 2022-07-26 Sanofi-Aventis Deutschland Gmbh Treatment protocol of diabetes type 2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE29924609U1 (de) * 1999-05-28 2004-04-22 Probiodrug Ag Neue Effektoren von Dipeptidylpeptidase IV
US20030139434A1 (en) * 2000-01-21 2003-07-24 Bork Balkan Combinations comprising dipeptidylpeptidase-iv inhibitor
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
JP2005527504A (ja) * 2002-02-28 2005-09-15 プロシディオン・リミテッド グルタミニルを基礎するｄｐｉｖ阻害剤
EP1543023B1 (en) * 2002-09-18 2010-03-17 Prosidion Limited Secondary binding site of dipeptidyl peptidase iv (dp iv)

Also Published As

Publication number Publication date
IL173844A0 (en) 2006-07-05
WO2005020983A3 (en) 2005-07-28
CN1845731A (zh) 2006-10-11
AU2004267955A1 (en) 2005-03-10
MXPA06002127A (es) 2006-05-31
ZA200601770B (en) 2007-07-25
EP1663200A2 (en) 2006-06-07
EA200600356A1 (ru) 2006-08-25
US20060287251A1 (en) 2006-12-21
NO20061085L (no) 2006-05-31
KR20060119927A (ko) 2006-11-24
JP2007504213A (ja) 2007-03-01
WO2005020983A2 (en) 2005-03-10
CA2536432A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
BR0107901A (pt) Composto, composição farmacêutica, método para o trtamento de enfermidade, para o trtamento e/ou prevenção de condições mediadas por receptores nucleares, e para o tratamento e/ou prevenção de diabetes e/ou obesidade, uso de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância à gligose prejudicada, resistência à insulina ou obesidade
WO2004110375A3 (en) Combination therapy for the treatment of diabetes
BRPI0508098A (pt) compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
BG103671A (en) Combinations of sulphonylcarbamide-glytazone having synergetic effect for the treatment of diabetes
BRPI0414062A (pt) uso de ciclosporinas midificadas para o tratamento de distúrbios por hcv
NO20071144L (no) Middel for a tilveiebringe substrater basert pa cellulose og/eller stivelse med vannfrastotende og samtidig soppdrepende, antibakterielle, insektfrastotende og algemotvirkende egenskaper
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
BR0206847A (pt) Tratamento do diabete melito
CL2006003672A1 (es) Compuestos derivados de pirimido-[4,5-b]-oxazinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes mellitus y/u obesidad.
WO2003059942A3 (en) Peptides and peptidomimetics having anti-proliferative activity and their use
BR0313792A (pt) Utilização de proteìna de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
BR0315314A (pt) Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente com necessidade do mesmo
GB0327380D0 (en) Method
BRPI0417451A (pt) método de tratar um tumor resistente a interferon
BRPI0413204A (pt) terapia de combinação para controle glicêmico
NO20075695L (no) Fremgangsmate til a behandle eller forhindre type-2 diabetes
BR0308634A (pt) Uso de um adenovìrus, e, composição
BRPI0412182A (pt) composição para tratamento e/ou prevenção de disfunções associadas com diabetes melito do tipo 2 e resistência à insulina
BR0103209A (pt) Uso de ácido fitânico para o tratamento de diabetes
WO2006017171A3 (en) Methods of diagnosing & treating obesity, diabetes and insulin resistance
WO2003101284A3 (en) Methods of diagnosing and treating diabetes and insulin resistance
BRPI0507194A (pt) processo para reduzir o conteúdo e cianeto de hidrogênio em misturas compreendendo penteno-nitrilas e cianeto e hidrogênio, e, uso de 1,3-butadieno
BRPI0508084A (pt) método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo
BRPI0417993A (pt) anticorpo anti-cd52 para tratamento da diabetes
BRPI0506793A (pt) métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.